BioAge Labs, Inc. - 10-Q Filing

BioAge Labs, Inc. reports Q3 2025 financial results highlighting collaborative revenue from Novartis Pharma AG and ongoing R&D expenditures.

SEC EDGAR ·

Tickers: $BIOA

Read the full article at SEC EDGAR

More Regulatory news